Dna Testing Centers Corp Receivables Turnover Ratio (DNAT), from the fourth quarter 2018 to the fourth quarter 2017 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Dna Testing Centers Corp  (DNAT)
 

Dna Testing Centers Accounts Receivables Turnover Ratio from the fourth quarter 2018 to the fourth quarter 2017

Quarterly Results, Trends, Rankings, Statistics


Dna Testing Centers Corp's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the fourth quarter 2018 to a ratio of 33.57, above the company average. This is a clear sign of healthy business climate in the In Vitro & In Vivo Diagnostic Substances industry and improving liquidity at their respective customers, during the fourth quarter 2018. Average receivable collection period, for the Dna Testing Centers in Dec 31 2018 quarter, has decreased to 11 days, compared to 12 days, in the Dec 31 2017 quarter.

If we take a look into Healthcare sector 125 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Dec 31 2018 from 237 to 1474.

What is Receivable Turnover Ratio?
What is Dna Testing Centers Corp Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DNAT Receivables Turnover Ratio (Dec 31 2018)
IV. Quarter		 (Dec 31 2017)
IV. Quarter		 (Sep 30 2017)
III. Quarter		 (Jun 30 2017)
II. Quarter		 (Mar 31 2017)
I. Quarter
Y / Y Receivable Change -91.6 % - -74.85 % 548.55 % 1758.54 %
Y / Y Revenue Change - -47.89 % 0.77 % 185.45 % 351.64 %
Receivable Turnover Ratio (TTM) 33.57 30.16 24.44 17.02 16
DNAT's Total Ranking # 1474 # 237 # # #
Accounts Receivable average collection period days 11 12 15 21 23
Seq. Receivable Change - - -41.44 % -26.38 % 26.47 %
Seq. Revenue Change - -50.4 % -30.84 % 6.63 % 42.47 %


Receivable Turnover Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 3
Healthcare Sector # 126
Overall Market # 1474

Receivable Turnover Ratio Statistics
High Average Low
4.84 2.52 0.92
(Jun 30 2017)   (Jun 30 2016)





DNAT Company Profile • Back to DNAT Efficiency Comparisons • Compare DNAT Receivables Turnover Ratio to its Competitors

Financial Statements
Dna Testing Centers's Accounts Receivable $ 0 Millions Visit DNAT's Balance sheet
Dna Testing Centers's Sales TTM $ 0 Millions Visit DNAT's Income Statement
Sources of DNAT's Revenues Visit DNAT's Sales by Geography

Other Accounts Receivable Turnover Ratios
In Vitro & In Vivo Diagnostic Substances Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
DNAT's Receivable Turnover Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
DNAT's Growth Rates DNAT's Roa DNAT's Inventory Turnover Ratio DNAT's Dividend Comparisons
DNAT's Profitability Ratios DNAT's Roi DNAT's Asset Turnover Ratio DNAT's Dividend Growth
DNAT's Valuation Ratios DNAT's Roe DNAT's Financial Strength Ratios DNAT's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Dec 31 2018, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Dec 31 2018 Receivable at quarter ending Dec 31 2018
Icon Plc  292.02 $ 2,595.777  Millions$ 8.889  Millions
Correvio Pharma Corp   281.12 $ 28.674  Millions$ 0.102  Millions
Siga Technologies Inc  276.90 $ 477.053  Millions$ 1.723  Millions
Arrowhead Pharmaceuticals Inc   275.74 $ 47.290  Millions$ 0.172  Millions
Zymeworks Inc   220.22 $ 53.019  Millions$ 0.241  Millions
Scorpius Holdings inc   199.05 $ 5.794  Millions$ 0.029  Millions
Qiagen N v   162.01 $ 1,501.848  Millions$ 9.270  Millions
U s Stem Cell Inc   154.18 $ 6.701  Millions$ 0.043  Millions
Nymox Pharmaceutical Corporation  149.50 $ 0.299  Millions$ 0.002  Millions
Concert Pharmaceuticals Inc   134.68 $ 10.505  Millions$ 0.078  Millions
Reliv International Inc  133.87 $ 36.116  Millions$ 0.270  Millions
Lifevantage Corp  111.56 $ 218.371  Millions$ 1.958  Millions
Editas Medicine Inc   93.52 $ 31.937  Millions$ 0.342  Millions
United Cannabis Corp  88.25 $ 7.245  Millions$ 0.082  Millions
Innovage Holding Corp   85.61 $ 23.990  Millions$ 0.280  Millions
Sigyn Therapeutics Inc   79.38 $ 0.541  Millions$ 0.007  Millions
Lifemd Inc   78.43 $ 8.324  Millions$ 0.106  Millions
Chemocentryx Inc.  78.03 $ 42.875  Millions$ 0.550  Millions
Ayala Pharmaceuticals Inc   62.32 $ 23.696  Millions$ 0.380  Millions
Decoy Therapeutics Inc   60.31 $ 0.918  Millions$ 0.015  Millions
U S Physical Therapy Inc  57.74 $ 453.911  Millions$ 7.861  Millions
Immunogen inc   55.66 $ 53.834  Millions$ 0.967  Millions
Nanomix Corp  47.40 $ 0.032  Millions$ 0.001  Millions
Oncomed Pharmaceuticals Inc  46.64 $ 44.421  Millions$ 0.952  Millions
Athersys Inc  45.42 $ 24.291  Millions$ 0.535  Millions
Nature s Sunshine Products inc   45.21 $ 364.810  Millions$ 8.069  Millions
Nektar Therapeutics  37.86 $ 1,193.323  Millions$ 31.518  Millions
Ardelyx inc   36.98 $ 2.607  Millions$ 0.071  Millions
Sonida Senior Living Inc   36.63 $ 460.018  Millions$ 12.559  Millions
Brookdale Senior Living Inc   35.72 $ 4,531.426  Millions$ 126.868  Millions

Date modified: 2026-08-30T10:51:15+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.